Podofilox
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Podofilox: From Genital Warts to Vulvovaginal Candidiasis
One-Sentence Summary
Podofilox (podophyllotoxin) is an antimitotic topical agent whose established clinical use — confirmed by the literature within this evidence pack — is the treatment of anogenital (genital) warts. The TxGNN model’s top-ranked prediction for this drug is Vulvovaginal Candidiasis, but this is supported by only 1 non-specific publication and no clinical trials, and the model’s own mechanistic review flags the prediction as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in taiwan_regulatory.licenses (drug not marketed); literature within this evidence pack documents established use for anogenital/genital warts (e.g. PMID 8192173, 9449907) |
| Predicted New Indication | Vulvovaginal Candidiasis |
| TxGNN Prediction Score | 99.47% |
| Evidence Level | L5 (model prediction only, no supportive studies) |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for podofilox is not available in this evidence pack (MOA: Data Gap). Based on the literature captured here, podofilox is a podophyllotoxin derivative with an antimitotic, cytotoxic mechanism, used topically to destroy wart tissue caused by human papillomavirus (HPV) infection — its proven original use is anogenital warts, not an antifungal or anti-infective indication.
Vulvovaginal candidiasis, by contrast, is a fungal infection requiring antifungal activity (e.g. azole or polyene agents) to clear Candida organisms. The evidence pack’s own mechanistic review is explicit on this point: podofilox has no antifungal activity and no established mechanistic relationship to candidiasis treatment. The single supporting reference (PMID 10537386) is a 1999 general review of sexually transmitted infection treatment guidelines that discusses vaginal discharge and genital warts as separate topics — it does not specifically link podofilox to candidiasis therapy.
Taken together, this appears to be a high-confidence TxGNN embedding-space association (both diseases occur in the genital tract, and podofilox is heavily associated with genital pathology in the knowledge graph) rather than a mechanistically grounded repurposing signal. This pattern — high similarity score, absent direct mechanistic support — is consistent with the L5/Hold classification.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10537386 | 1999 | Review | American Family Physician | General CDC-guideline review of STD/vaginal infection treatment; does not specifically address podofilox for vulvovaginal candidiasis |
UK Market Information
Podofilox is currently not marketed in the UK, and no marketing authorisations are recorded in this evidence pack (0 licenses).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN similarity score (99.47%), the evidence base for this prediction is minimal (L5) and the model’s own mechanistic rationale explicitly contradicts biological plausibility — podofilox is an antimitotic cytotoxic agent with no antifungal activity, and its sole supporting reference does not address this indication. This candidate should not proceed without substantial new evidence.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or SmPC
- MHRA/SmPC warnings, contraindications and DDI data (currently all Data Gap)
- Preclinical or in vitro evidence of any antifungal or anti-Candida activity, given none currently exists
- Note: the co-occurring predicted indication “Human Papilloma Virus Infection” (rank 3 in this evidence pack) is far better supported by existing literature and clinical trial data and may warrant separate, prioritised evaluation instead of this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.